Liquid chromatography tandem mass spectrometry assay for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in human plasma and its application to a bioequivalence study

Journal of Pharmaceutical and Biomedical Analysis

Volumn 47, Issue 3, 2008, Pages 603-611

  Patel, Bhavin N ^a,b   Sharma, Naveen ^b   Sanyal, Mallika ^c   Shrivastav, Pranav S ^a  

^a GUJARAT UNIVERSITY   (India)

^b BA Research India Limited   (India)

^c ST XAVIER S COLLEGE   (India)

Author keywords

Bioequivalence study; Human plasma; LC MS MS; O Desmethylvenlafaxine; Protein precipitation; Venlafaxine

Indexed keywords

ACETONITRILE; DESVENLAFAXINE; FORMIC ACID; ION; NADOLOL; PROTEIN; VENLAFAXINE;

ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DILUTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG FORMULATION; DYNAMICS; ELECTROSPRAY; FEEDING; HUMAN; INDIAN; LIQUID CHROMATOGRAPHY; MALE; MONITORING; PLASMA; PRECIPITATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STANDARD; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; CYCLOHEXANOLS; DRUG STABILITY; HUMANS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY;

EID: 43949120415     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2008.02.015     Document Type: Article

References (31)

1. Muth E.A., Haskins J.T., Moyer J.A., Husbands G.E.M., and Andree T.H. Drug Dev. Res. 23 (1991) 191-199
2. Makhija S.N., and Vavia P.R. J. Pharm. Biomed. Anal. 28 (2002) 1055-1059
3. Muth E.A., Haskins J.T., Moyer J.A., Husbands G.E.M., Nielson S.T., and Sigg E.B. Biochem. Pharmacol. 35 (1986) 4493-4497
4. Lacassie E., Gaulier J.M., Marquet P., Rabatel J.F., and Lachatre G. J. Chromatogr. B 742 (2000) 229-238
5. Andrews J.M., Ninan P.T., and Nemeroff C.B. Depression 4 (1996) 48-56
6. Hicks D.R., Wolaniuk D., Russell A., Cavanaugh N., and Kraml M. Ther. Drug Monit. 16 (1994) 100-107
7. Rudorfer M.V., and Potter W.Z. CNS Drugs 7 (1997) 273-312
8. Sisenwine S.F., Politowski J., Birk K., White G., and Dyroff M. Acta Pharmacol. Toxicol. 59 (1986) 312-316
9. Dollery C. Therapeutic Drugs. second ed. (1999), Churchill Livingstone, London
10. Frahnert C., Rao M.L., and Grasmader K. J. Chromatogr. B 794 (2003) 35-47
11. Castaing N., Titier K., Receveur-Daurel M., Le-Deodic M., Le-bars D., Moore N., and Molimard M. J. Anal. Toxicol. 31 (2007) 334-341
12. Wille S.M.R., Maudens K.E., Peteghem C.H.V., and Lambert W.E.E. J. Chromatogr. A 1098 (2005) 19-29
13. Gunnar T., Mykkanen S., Ariniemi K., and Lillsunde P. J. Chromatogr. B 806 (2004) 205-219
14. Long C., Crifasi J., Magnin D., Graham M., and Teas S. J. Anal. Toxicol. 21 (1997) 166-169
15. Titier K., Castaing N., Scotto-Gomez E., Pehourcq F., Moore N., and Molimard M. Ther. Drug Monit. 25 (2003) 581-587
16. Desiderio C., Aturki Z., and Fanali S. Electrophoresis 22 (2001) 535-543
17. Cherkaoui S., Rudaz S., Varesio E., and Veuthey J.L. Electrophoresis 22 (2001) 3308-3315
18. Rudaz S., Stella C., Balant-Gorgia A.E., Fanali S., and Veuthey J.L. J. Pharm. Biomed. Anal. 23 (2000) 107-115
19. Fanali S., Rudaz S., Veuthey J.L., and Desiderio C. J. Chromatogr. A 919 (2001) 195-203
20. Liu W., Wang F., and Li H. J. Chromatogr. B 850 (2007) 183-189
21. Wei Z., Bing-Ren X., and Cai-Yun W. Biomed. Chromatogr. 21 (2007) 266-272
22. Theron H.B., van der Merwe M.J., Swart K.J., and van der Westhuizen J.H. Rapid Commun. Mass Spectrom. 21 (2007) 1680-1686
23. Matoga M., Pehourcq F., Titier K., Dumora F., and Jarry C. J. Chromatogr. B 760 (2001) 213-218
24. Vu R.L., Helmeste D., Albers L., and Reist C. J. Chromatogr. B 703 (1997) 195-201
25. Mandrioli R., Mercolini L., Cesta R., Fanali S., Amore M., and Raggi M.A. J. Chromatogr. B 856 (2007) 88-94
26. Clement E.M., Odontiadis J., and Franklin M. J. Chromatogr. B 705 (1998) 303-308
27. Bhatt J., Jangid A., Venkatesh G., Subbaiah G., and Singh S. J. Chromatogr. B 829 (2005) 75-81
28. Liu W., Cai H., and Li H. J. Chromatogr. B 850 (2007) 405-411
29. Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM), May, 2001.
30. FDA Guidance for Industry: Bioavailability Studies for Orally Administered Drug-Products-General Considerations, U.S. Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), 2000.
31. Charlier C., Pinto E., Ansseau M., and Plomteux G. J. Psychopharmacol. 16 (2002) 369-372